Clinical Trial Results: IO Biotech's Melanoma Drug Nearly Doubles Survival Time vs Standard Treatment
StockTitan   20 days ago
ads
Read Full Story
Clinical Trial Results: IO Biotech's Melanoma Drug Nearly Doubles Survival Time vs Standard Treatment  Stock TitanIO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a...